| Fund Name | Location |
| Aeternity | Liechtenstein, Oberland, Vaduz |
| Amelia Investments | - |
| Dauk/Wagner Investments | Connecticut, Ridgefield, United States |
| Garnett & Helfrich Capital | California, San Mateo, United States |
| Guangdong Bangsheng Zichan Guanli | China, Guangdong, Guangzhou |
| HealthCare Biotech | China, Hubei, Wuhan |
| IDATEN Ventures | Chiba, Japan, Minato |
| Maple Capital Advisors | - |
| Nakashimato | Chiyoda, Japan |
| Qujingshi Qilinqu Gongye Yuanqu Kaifa Touzi | China, Qujing, Yunnan |
| RWE | Essen, Germany, Nordrhein-Westfalen |
| SBS Ventures | - |
| Shenzhenshi Huaxia Dexin Jijin Guanli Youxian Gongsi | China, Guangdong Province, Huizhou |
| Somerset Capital | Colorado, Denver, United States |
| Techstars Metro Retail | Berlin, Berlin, Germany |
| The Angel Roundtable | Johnson City, Tennessee, United States |
| UVA Licensing & Ventures Group | Charlottesville, United States, Virginia |
| Xinbaijia Wenhua Chuanbo | China, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Riboko | 27 Mar 2023 | Beijing, Beijing, China | |||
Xilingyuan Pharmaceutical | $13M | 25 Nov 2022 | Chengdu, Sichuan, China | ||
Junyi Technology | 09 May 2022 | Shenzhen, Guangdong, China | |||
| 22 Oct 2019 | Qingyang District, Sichuan, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Riboko | 27 Mar 2023 | Beijing, Beijing, China | |||
Xilingyuan Pharmaceutical | $13M | 25 Nov 2022 | Chengdu, Sichuan, China | ||
Junyi Technology | 09 May 2022 | Shenzhen, Guangdong, China | |||
| 22 Oct 2019 | Qingyang District, Sichuan, China |
